SNT:JSESantam Limited Analysis
Data as of 2026-05-26 - not real-time
ZAC 38,141.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Santam Ltd (SNT.JO) is trading at ZAc 38,141, well below its 30‑day DCF fair value of ZAc 205,262, implying a substantial valuation gap. The stock’s price sits beneath the 20‑day (ZAc 39,045), 50‑day (ZAc 39,804) and 200‑day (ZAc 41,508) simple moving averages, confirming a bearish technical backdrop. Nevertheless, the RSI of 39.4 suggests the shares are approaching oversold territory, hinting at a possible short‑term rebound. The MACD line remains negative with a bearish histogram, reinforcing current downside momentum. At a dividend yield of 4.36 % and a payout ratio of 42.8 %, the dividend appears sustainable, offering attractive income. The market’s “Extreme Greed” sentiment (fear‑greed index 91.6) further fuels upside potential.
Fundamentally, Santam delivers solid growth with 4.9 % revenue expansion, a robust ROE of 33 % and operating margins near 19 %, outpacing many peers. Its price‑to‑earnings multiple of 10.4 is well under the industry average of 16.8, underscoring a value‑oriented entry point. Low beta (0.15) and moderate 30‑day volatility (16.8 %) indicate limited systematic risk, though liquidity is constrained by thin trading volumes. The consensus “Buy” rating, a mean target price of ZAc 47,543 and an upside estimate of roughly 25 % align with a longer‑run appreciation thesis. Given the strong balance sheet, modest debt levels and a resilient dividend, the stock is positioned for sustained performance. Investors should therefore consider accumulating on dips while monitoring support at ZAc 36,100.
Fundamentally, Santam delivers solid growth with 4.9 % revenue expansion, a robust ROE of 33 % and operating margins near 19 %, outpacing many peers. Its price‑to‑earnings multiple of 10.4 is well under the industry average of 16.8, underscoring a value‑oriented entry point. Low beta (0.15) and moderate 30‑day volatility (16.8 %) indicate limited systematic risk, though liquidity is constrained by thin trading volumes. The consensus “Buy” rating, a mean target price of ZAc 47,543 and an upside estimate of roughly 25 % align with a longer‑run appreciation thesis. Given the strong balance sheet, modest debt levels and a resilient dividend, the stock is positioned for sustained performance. Investors should therefore consider accumulating on dips while monitoring support at ZAc 36,100.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below key moving averages indicating bearish trend
- RSI near oversold levels suggesting potential bounce
- Thin trading volume increasing short‑term execution risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation upside to DCF fair value
- Strong ROE and low PE relative to industry
- Sustainable dividend yield supporting total return
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Robust balance sheet with low leverage
- Consistent earnings growth and high ROE
- Long‑term dividend sustainability and attractive yield
Key Metrics & Analysis
Financial Health
Revenue Growth4.90%
Profit Margin6.63%
P/E Ratio10.4
ROE33.08%
ROA8.78%
Debt/Equity37.14
P/B Ratio2.8
Op. Cash FlowZAC2.4B
Free Cash FlowZAC13.0B
Industry P/E16.8
Technical Analysis
TrendBearish
RSI39.4
SupportZAC 36,100.00
ResistanceZAC 41,176.00
MA 20ZAC 39,045.55
MA 50ZAC 39,804.60
MA 200ZAC 41,507.52
MACDBearish
VolumeStable
Fear & Greed Index91.64
Valuation
Fair ValueZAC 205,262.34
Target PriceZAC 47,543.83
Upside/Downside24.65%
GradeUndervalued
TypeBlend
Dividend Yield4.36%
Risk Assessment
Beta0.15
Volatility16.80%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.